Evidence Hub

The efficacy of sotalol in suppressing ventricular ectopic beats

Myburgh DP, Goldman aP, Cartoon J, Schamroth JM

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1979

20 participants

Abstract

Sotalol (Sotacor) is a beta-adrenergic receptor blocking agent, which in addition possesses class III anti-arrhythmic properties. In this study we report on the clinical effectiveness of sotalol in the suppression of ventricular ectopic beats in 20 patients suffering from ischaemic heart disease. Sotalol was compared with placebo and efficacy was determined by Holter tape monitoring. Sotalol produced an 88,5% (P < 0,001) reduction in ectopic beat frequency at the optimal titrated dosage, with relatively few physical or biochemical side-effects. In situations where ventricular anti-arrhythmic therapy is deemed necessary, especially if long-term use is considered, sotalol seems to be the agent of choice.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free